Addario Lung Cancer Medical Institute (ALCMI)

Boosting Treatments Against Aggressive Lung Cancer - News Center A new study has uncovered a promising way to improve treatment for small cell lung cancer, one of the most aggressive and deadly forms of cancer, according to findings published in The Journal of…

Investigators have uncovered a promising new mechanism to improve treatment for small-cell lung cancer! #lungcancer
news.feinberg.northwestern.edu/2025/07/30/b...

Behind the FDA Approval of Dato-DXd in Lung Cancer With Dr Sands Jacob Sands, MD, discusses the data that support the FDA accelerated approval of Dato-DXd in EGFR-positive non–small cell lung cancer.

Great insights from our friend Dr. Jacob Sands from Dana-Farber Cancer Institute. Dr. Sands joined Targeted Oncology to talk about the FDA’s accelerated approval of datopotamab deruxtecan (Dato-DXd) in post-EGFR NSCLC treatment. #lungcancer
www.targetedonc.com/view/behind-...

Machine learning model improves treatment selection in non-small cell lung cancer A team led by Jia Wu, Ph.D., used over 2,300 cases from four different cancer centers to develop a machine learning model called A-STEP (Attention-based Scoring for Treatment Effect Prediction) that…

Jia Wu, Ph.D., and colleagues at MD Anderson Cancer Center have developed a machine learning model called "A-STEP" that predicts whether a patient is likely to benefit more from combination therapy or monotherapy. #lungcancer
www.mdanderson.org/newsroom/res...

COCOON Regimen Shows Promise in Mitigating Dermatologic AEs During NSCLC Treatment A proactive regimen reduces dermatologic AEs in patients with NSCLC who were treated with amivantamab and lazertinib, enhancing treatment adherence.

A significant hurdle in NSCLC treatment with amivantamab and lazertinib has been the debilitating dermatologic adverse events that compromise patient adherence and quality of life. New data from the phase 2 COCOON trial challenge this issue. #lungcancer
www.cancernetwork.com/view/cocoon-...

On this day of reflection, we honor every person who has faced lung cancer, the physicians who help them fight, the advocates working to raise awareness, and the researchers who are leading us toward a brighter future.
#worldlungcancerday #lungcancer

KRASG12C-mutant NSCLC remains a clinical and economic sinkhole, and new real-world data from Spain puts hard numbers behind that reality. #lungcancer
www.sciencedirect.com/science/arti...

The SUCCEED Study, led by Dr. Christine Lovly, is now enrolling patients. Learn more at alcmi.org/clinical-tri...
#lungcancer #sclc

“CyPath® Lung gave us the clarity we needed to act early,” said Dr. Gordon Downie, CMO, referring to a Stage 1A mucinous adenocarcinoma missed by other diagnostics.
Every early diagnosis is a life potentially saved.
Read the press release: bit.ly/4l6uOvn
#CyPathLung #LungCancer #bioAffinity

FDA Fast Tracks DB-1310 for Advanced Nonsquamous Lung Cancer The FDA granted fast track status to DB-1310, a HER3-targeting antibody-drug conjugate, for advanced nonsquamous non-small cell lung cancer.

The FDA has fast-tracked DB-1310, a HER3-targeting advanced nonsquamous NSCLC with EGFR exon 19 deletions or L858R mutations. #lungcancer
www.curetoday.com/view/fda-fas...

Radiation Therapy Overcomes Immunotherapy Resistance in Some Cancers 07/22/2025

New data from Johns Hopkins Medicine and The Netherlands Cancer Institute indicated that adding radiation to immunotherapy in lung cancer helped overcome primary resistance. #lungcancer
www.hopkinsmedicine.org/news/newsroo...

Allergies linked to lower lung cancer risk, new study finds A meta-analysis of nearly 3.9 million participants shows people with allergies have significantly lower odds of developing lung cancer. Allergic rhinitis is particularly protective, while eczema’s…

New evidence links allergic rhinitis to lower lung cancer risk, especially in men. A meta-analysis of 3.8 million individuals found that individuals with allergic rhinitis had a 26% reduction in lung cancer odds. #lungcancer
www.news-medical.net/news/2025072...

Final overall survival data from the FLAURA2 Phase III trial confirm that combining osimertinib with platinum-based chemotherapy significantly extends the lives of patients with 1st-line EGFR-mutated advanced NSCLC compared to those on monotherapy. #lungcancer
www.astrazeneca.com/media-centre...

A Major Award Means ‘Time to Think’ About One of Lung Cancer’s Mysteries CU Cancer Center member Tejas Patil, MD, is chosen for the NCI-backed Paul Calabresi Clinical Scholars Award to support career development.

Congratulations to Dr. Tejas Patil from the University of Colorado Cancer Center, who was recently awarded the National Cancer Institute (NCI)’s prestigious Paul Calabresi Clinical Scholars Award! #lungcancer
news.cuanschutz.edu/cancer-cente...

Nadunolimab Combo Exhibits Early Efficacy in Advanced NSCLC Particularly strong efficacy signals were observed in patients with non-squamous non–small cell lung cancer previously treated with PD-1 inhibition.

A recent publication in Lung Cancer details compelling early efficacy data for nadunolimab (CAN04) in combination with platinum-based chemotherapy for advanced non–small cell lung cancer from the Phase 2a CANFOUR trial. #lungcancer
www.cancernetwork.com/view/nadunol...

Microplastics found to trigger cancer-linked changes in lung cells Although the respiratory system is one of the main entry points for microplastics and nanoplastics (MNPs) from the air into the body, little is known about the effects of these tiny particles on the…

New research shows that healthy lung cells exhibit early oncogenic behavior after exposure to airborne microplastics. #lungcancer
www.news-medical.net/news/2025071...

Factors linked to lung cancer in never-smokers A study linked fine-particle air pollution and other environmental factors to genetic changes in people with lung cancer who never smoked.

A recent study published in Nature offers compelling evidence, directly linking fine-particle air pollution and other environmental factors to specific genetic changes in lung tumors of never-smokers. #lungcancer
www.nih.gov/news-events/...

Concomitant Use of Analgesics and EGFR TKIs in Lung Cancer Patients: Outcomes and Perspectives From a Finnish Retrospective Register-Based Study - PubMed In EGFR TKI-treated NSCLC, opioids are an independent risk factor for worse ToT and OS. The outcomes differed by immunomodulatory category of opioids, suggesting analgesics class can potentially have…

New Finnish data raises red flags on opioid use in EGFR+ NSCLC treatment. #lungcancer
pubmed.ncbi.nlm.nih.gov/40650440/

Targeted radiation offers promise in patients with metastasized small cell lung cancer to the brain A new study led by investigators from Mass General Brigham trialed stereotactic (targeted) brain-directed radiation in 100 patients with small cell lung cancer and brain metastases, finding they…

A clinical shift may be on the horizon for managing small cell lung cancer with brain metastases. #lungcancer
medicalxpress.com/news/2025-07...

EAGLE model predicts key lung cancer mutations from routine biopsy With EAGLE, lung cancer biopsy analysis is expedited, accurately predicting EGFR mutations and streamlining the diagnostic process for better patient outcomes.

A new AI tool is transforming the timeline and tissue burden of EGFR testing in lung adenocarcinoma. #lungcancer
www.news-medical.net/news/2025071...

'Seesaw' may explain why lung cancer treatments stop working Researchers have discovered a hidden "molecular seesaw" behind drug resistance in certain types of lung cancer.

Research from the University of Missouri-Columbia, School of Medicine has found a molecular "seesaw" involving the AXL and FN14 proteins. This mechanism explains why lung cancer tumors can evade targeted drug therapies. #lungcancer
www.futurity.org/why-lung-can...

FDA OKs New Test to Match Lung Cancer Patients With Targeted Therapies The U.S. FDA has approved a new test for patients with lung cancer to match the correct individuals with a targeted treatment called Zegfrovy.

The FDA has approved a new test from Thermo Fisher Scientific to quickly match lung cancer patients to life-extending targeted therapy. #lungcancer
www.curetoday.com/view/fda-oks...

: Loyola University Chicago July 9, 2025 – CHICAGO – Respiratory Health Association is proud to present the 2025 Lung Cancer Research Award to Nan Sethakorn, MD, PhD. She is an Assistant Professor of Medicine at Loyola…

Congratulations to Dr. Nan Sethakorn at Loyola University Chicago Stritch School of Medicine! Dr. Sethakorn recently received the Respiratory Health Association's 2025 Lung Cancer Research Award for research into using immune cells to combat lung cancer. #lungcancer
www.luc.edu/stritch/stor...

New data from Sweden may shift how we assess lung cancer risk, especially in patients with interstitial lung disease (ILD). #lungcancer
jamanetwork.com/journals/jam...

Corticosteroids may reduce effectiveness of immunotherapy in lung cancer Corticosteroids, a commonly prescribed medication to alleviate cancer-related symptoms for non-small cell lung cancer patients treated with immunotherapy, are the main reason certain immunotherapies…

A recent study from Keck Medicine of USC presents compelling data that challenges current co-treatment protocols in non-small cell lung cancer, specifically regarding the concurrent use of corticosteroids with immune checkpoint inhibitors (ICIs). #lungcancer
www.news-medical.net/news/2025070...

Calling all lung cancer physicians and researchers! If you’re caring for patients with small cell lung cancer, we invite you to refer eligible individuals to the SUCCEED Study, a prospective observational study now enrolling people across the U.S. #lungcancer #sclc

Alzheimer’s protein found to drive lung cancer spread to the brain Researchers at McMaster University, Cleveland Clinic and Case Comprehensive Cancer Center have uncovered how a protein long associated with Alzheimer's disease helps lung cancer spread to the brain –…

BACE1, a protein linked to Alzheimer's, is now thought to be a key driver of lung cancer brain metastases. #lungcancer
www.news-medical.net/news/2025070...

Congratulations to City of Hope's Kristin Higgins, MD, on her appointment as Chair of the NRG Oncology Lung Cancer Committee, effective August 1. #lungcancer
www.cityofhope.org/locations/at...

Advances in NSCLC Bring Excitement in the Lung Space According to Jorge Nieva, MD, there are a multitude of things that can be explored to enhance the treatment landscape for lung cancer.

In a new Cancer Network commentary, our friend Dr. Jorge Nieva outlines the growing momentum behind bispecific T-cell engagers, particularly in SCLC. #lungcancer
www.cancernetwork.com/view/advance...

Air Pollution 'Strongly Associated' With DNA Mutations Tied to Lung Cancer Lung cancer cases are on the rise in non-smokers around the world, and air pollution could be an insidious, contributing factor.

New evidence deepens the connection between air pollution and mutational drivers of lung cancer in never-smokers. #lungcancer
www.sciencealert.com/air-pollutio...

Clinicians have long lacked effective targeted options for patients with RIT1-altered lung adenocarcinoma, often classed “oncogene-negative” despite clear genomic abnormalities. A new study led by Dr. Danilo Maddalo at Genentech may change that. #lungcancer
aacrjournals.org/cancerres/ar...